Joint comfort
You want it preserved: protecting cartilage keeps joints mobile and comfortable with age.
In depth
Cartilage, synovium, subchondral bone and the tissues that load them. A finding the evidence shows: joint pain and joint structure come apart — pain 'may not correlate with inflammation or structural damage', so an intervention can help one and not the other.
What drives it
Calms inflammation reduces it.
NF-κB-in-OA review 2019, Cells — NF-κB signaling drives chondrocyte catabolism (MMPs/ADAMTS) and suppresses cartilage anabolism, degrading joint cartilage and impairing joint function. doi:10.3390/cells8070734. Joint function falls by the same route: NF-kappa-B-driven chondrocyte catabolism raises MMP-13 and ADAMTS-5, degrading aggrecan and COL2A1 while lowering Bcl-2 and raising cleaved caspase-3 and BAX. demonstrated in IL-1-beta-stimulated chondrocytes and DMM-induced OA mice, plus bovine and human chondrocyte culture -- these are induced models of joint damage, not normal joint physiology. doi 10.3390/cells8070734.
Supports weight management reduces it.
Body weight acts on the joint chemically as well as mechanically: obesity raises pro-inflammatory cytokines and degrading enzymes that inhibit cartilage matrix synthesis, and osteoarthritis shares inflammatory-aging, oxidative-stress and lipid-metabolism mechanisms with metabolic syndrome (PMC4842398). The load you carry and the inflammation you carry reach the same tissue by two different routes. PMC4842398
Headache peptide reduces it.
CGRP is not only a migraine mediator: clinical and preclinical evidence associates it with hip and knee joint pain. In 43 patients with radiographic knee osteoarthritis (Kellgren/Lawrence grade 3-4) undergoing total knee arthroplasty, CGRP and COX-2 localized to the synovial lining layer and COX-2 expression correlated positively with CGRP mRNA; cultured synovial cells raised CGRP on PGE2 and EP4-agonist treatment, and RAMP1 on EP1/EP2 agonists (PMC5067902). Verified at source. this is joint pain, a symptom, not cartilage loss or structural progression — and the authors state the regulation mechanisms of CGRP signaling in synovial tissue are not fully understood. Human synovium, end-stage OA only. PMC5067902
Joint wear reduces it.
NBK482326 — Joint function is the proximate consequence. Close to definitional and said so.
Balanced skin cell turnover reduces it.
10.3390/ijms24054901 — Psoriatic arthritis is a recognized progression. doi 10.3390/ijms24054901
Urate clearance reduces it.
MSU crystal deposition in articular and periarticular spaces causes acute flares and, untreated, structural joint damage and functional impairment. PMID 39712248 · PMC9723165
Bone-resorbing enzyme reduces it.
The same enzyme reaches cartilage. Verbatim: 'It degrades the two main types of collagen, I and II and is predominantly expressed in osteoclasts' (PMC2951121). Type I is the bone collagen, type II the cartilage collagen, so one protease acts on both center points. PMC2951121
Matrix-degrading enzymes reduces it.
Matrix metalloproteinases are the extracellular collagenase arm, working outside the cell where cathepsin K works inside its lysosomes and resorption lacunae. The cathepsin literature contrasts the two compartments directly. PMID 21718816
Tissue remodeling increases it.
10.1186/s12937-026-01302-0 — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). Verbatim: “In relation to skin, musculoskeletal health, and osteoarthritis conditions, collagen supplementation was consistently associated with favorable outcomes”. doi 10.1186/s12937-026-01302-0 · PMID 41809116
Calms body-wide inflammation reduces it.
10.1038/nrrheum.2016.136 — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). Verbatim: “n-3 PUFAs, mainly including eicosapentaenoic acid (EPA) and docosahexanoic acid (DHA), have been suggested to be effective for patients with OA because of their efficacy for attenuating the systemic inflammatory response and the catabolic environment that accelerates cartilage degradation”. doi 10.1038/nrrheum.2016.136 · PMID 37226250 · PMC10210278
Inflammatory alarm reduces it.
10.1038/s41413-026-00573-x — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). Verbatim: “Accumulating evidence indicates that nod-like receptor pyrin domain 3 (NLRP3) inflammasome-mediated pyroptosis of chondrocytes plays a crucial role in the OA progression”. doi 10.1038/s41413-026-00573-x · PMID 37506502
Inflammation signal (TNF-α) reduces it.
10.1002/j.1460-2075.1991.tb04978.x — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). doi 10.1002/j.1460-2075.1991.tb04978.x
Inflammatory signaling reduces it.
10.1186/s43166-022-00130-4 — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). Verbatim: “IL-17 disrupts the balance in cartilage matrix metabolism, and the resulting feedback affects the physiological function of chondrocytes, leading to cartilage tissue degeneration”. doi 10.1186/s43166-022-00130-4 · PMID 37854319 · PMC10579884
Oxidative stress reduces it.
10.1038/nrrheum.2010.213 — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). Verbatim: “Chondrocyte senescence and the resultant damage to cartilage tissue, induced by elevated levels of reactive oxygen species within the joint cavity, are significant causative factors in OA development”. doi 10.1038/nrrheum.2010.213
What it drives
It reduces Joint wear.
Named across six reviews of bone remodeling and osteoarthritis pathogenesis. Bone remodeling relies on the coordinated actions of bone-resorbing osteoclasts, bone-forming osteoblasts, and osteocytes serving as mechanosensors and local remodeling coordinators. PMC10648156
It reduces Urate clearance.
The architecture is unusually clean and worth stating: gout has two separable stages. Stage one is metabolic - urate underexcretion through renal and gut mechanisms is the major mechanism for hyperuricemia in most people, via URAT1, GLUT9 and ABCG2. Stage two is immunological - MSU crystals function as damage-associated molecular patterns which, upon phagocytosis by macrophages, activate the NLRP3 inflammasome through a two-step process: priming via NF-kB signaling and activation via lysosomal rupture, potassium efflux, and mitochondrial ROS. And the two stages come apart in people: not all individuals with hyperuricemia show deposition of MSU crystals OR develop gout. Local factors decide - reduced joint temperature, low pH, high sodium concentration, and preexisting joint damage. A urate number is not a diagnosis. The treatment target is explicit: long-term lowering of serum urate to less than 360 MICROMOL/L leads to crystal dissolution and ultimately to suppression of flares. PMID 39712248 · PMC8268734
It increases Physical performance.
10.1371/journal.pone.0217462 — This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome). doi 10.1371/journal.pone.0217462
It increases Mood.
This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome). Sources:. doi 10.1016/j.eclinm.2019.08.010.
It increases Sleep.
10.1186/s12877-026-07117-2 — This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome). doi 10.1186/s12877-026-07117-2
It increases Training load.
10.1177/2325967119878136 — 10.1177/1759720X241273009 — This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome). doi 10.1177/2325967119878136
It increases Muscle.
10.1038/s41598-024-58375-2 — This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome). doi 10.1038/s41598-024-58375-2
It increases Recovery.
This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome).
It increases Bone health.
https://www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/joint-disorders/osteoarthritis-oa — This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome).
It reduces Calm pain signaling.
This link rests on the reviews of this outcome as a whole. No effect size specific to this arm has been reported, so it is shown at reduced weight. (from the reviews of this outcome).
It increases Balance & falls.
10.3390/s25206288 — 37221150 — Drawn from reviews of neighboring outcomes rather than from studies of this outcome itself, which is weaker evidence, and the map marks it so. doi 10.3390/s25206288
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
Blends that reach it upstream
Each of these acts on a pathway that feeds this one. The step is named beneath the blend, and that pathway carries the study behind it.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.